Despite universal access to HER2 testing in Ontario, variability in reporting by region and disease severity presents challenges for program evaluation and quality improvement initiatives.
Eleanor Pullenayegum, PhD
Advertisement
Articles by Eleanor Pullenayegum, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology
2
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
3
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
4
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
5